Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | MME | P08473 | 8/20 | 0.53 |
| ▸ | ACE | P12821 | 7/20 | 0.50 |
| ▸ | CPA1 | P15085 | 5/20 | 0.50 |
| ▸ | ACE2 | Q9BYF1 | 5/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.48 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.46 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL838649 | 1.00 | NPC1 (0.54) | NPC1RAB9AMMEACECPA1 | |
| SCHEMBL7263049 | 0.98 | MME (0.52) | NPC1RAB9AMMEACECPA1 | |
| SCHEMBL10934246 | 0.92 | FOLH1 (0.51) | MMEACECPA1ACE2MEN1 | |
| SCHEMBL10934250 | 0.92 | FOLH1 (0.51) | MMEACECPA1ACE2MEN1 | |
| SCHEMBL6439790 | 0.88 | EPHX2 (0.56) | MMEACECPA1ACE2EPHX2 | |
| SCHEMBL6439794 | 0.88 | EPHX2 (0.56) | MMEACECPA1ACE2EPHX2 | |
| SCHEMBL29069408 | 0.88 | EPHX2 (0.56) | MMEACECPA1ACE2EPHX2 | |
| SCHEMBL10889174 | 0.87 | MME (0.44) | NPC1RAB9AMMEACECPA1 | |
| SCHEMBL10889181 | 0.87 | MME (0.44) | NPC1RAB9AMMEACECPA1 | |
| SCHEMBL12678083 | 0.86 | MME (0.54) | MMEACECPA1ACE2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1109831-B1 | CYCTOTOXIC PEPTIDES MODIFIED BY BULKY OR LIPOPHILIC MOIETIES | LYTIX BIOPHARMA AS (NO) | 2011-01-12 | — | — | EP | claimed |
| EP-1247870-A2 | Test system for the determination of proteases, active in-vivo in haemostasis, in biological fluids | Stief, Thomas, Dr. (DE) | 2002-10-09 | — | — | EP | claimed |
| US-20250002854-A1 | METHODS OF GENERATING POPULATIONS OF TUMOUR-INFILTRATING T CELLS | VERRICA PHARMACEUTICALS INC. | 2025-01-02 | — | — | US | disclosed |
| US-20190038670-A1 | METHODS OF GENERATING POPULATIONS OF TUMOUR-INFILTRATING T CELLS | LYTIX BIOPHARMA AS (NO) | 2019-02-07 | — | — | US | disclosed |
| EP-3411049-A1 | METHODS OF GENERATING POPULATIONS OF TUMOUR-INFILTRATING T CELLS | Lytix Biopharma AS (NO) | 2018-12-12 | — | — | EP | disclosed |
| WO-2018188761-A1 | METHOD OF REDUCING POPULATION SIZE OF TREGS AND/OR MDSCS | LYTIX BIOPHARMA AS (NO) | 2018-10-18 | — | — | WO | disclosed |
| WO-2017134175-A1 | METHODS OF GENERATING POPULATIONS OF TUMOUR-INFILTRATING T CELLS | LYTIX BIOPHARMA AS (NO) | 2017-08-10 | — | — | WO | disclosed |
| US-9115169-B2 | Method of treating tumors | LYTIX BIOPHARMA AS (NO) | 2015-08-25 | — | — | US | disclosed |
| US-9109048-B2 | Inhibition of tumor growth | LYTIX BIOPHARMA AS (NO) | 2015-08-18 | — | — | US | disclosed |
| US-20140037657-A1 | INHIBITION OF TUMOR GROWTH | LYTIX BIOPHARMA AS (NO) | 2014-02-06 | — | — | US | disclosed |
| US-8283315-B2 | Inhibition of tumour growth | LYTIX BIOPHARMA AS (NO) | 2012-10-09 | — | — | US | disclosed |
| EP-1109831-A2 | CYCTOTOXIC PEPTIDES MODIFIED BY BULKY OR LIPOPHILIC MOIETIES | ALPHARMA AS (NO) | 2001-06-27 | — | — | EP | disclosed |
| EP-1109827-A2 | BIOACTIVE PEPTIDES | ALPHARMA AS (NO) | 2001-06-27 | — | — | EP | disclosed |
| WO-2001019852-A2 | METHODS OF PEPTIDE PREPARATION | ALPHARMA AS (NO) | 2001-03-22 | — | — | WO | disclosed |
| WO-2000012542-A2 | CYTOTOXIC LACTOFERRIN DERIVATIVES MODIFIED BY BULKY OR LIPOPHILIC MOIETIES | ALPHARMA AS (NO) | 2000-03-09 | — | — | WO | disclosed |
| WO-2000012541-A2 | CYTOTOXIC PEPTIDES MODIFIED BY BULKY OR LIPOPHILIC MOIETIES | ALPHARMA AS (NO) | 2000-03-09 | — | — | WO | disclosed |
| EP-0486515-B1 | A method for determining the functional activity of free protein S or protein C in a plasma sample | CHROMOGENIX AB (SE) | 1995-09-13 | — | — | EP | disclosed |
| US-5439802-A | Adding factor ix or factor v; measurement thrombin formed | CHROMOGENIX AB (SE) | 1995-08-08 | — | — | US | disclosed |
| EP-0486515-A1 | A METHOD FOR DETERMINING THE FUNCTIONAL ACTIVITY OF FREE PROTEIN S OR PROTEIN C IN A PLASMA SAMPLE. | KABI PHARMACIA AB (SE) | 1992-05-27 | — | — | EP | disclosed |
| WO-1991001382-A1 | A METHOD FOR DETERMINING THE FUNCTIONAL ACTIVITY OF FREE PROTEIN S OR PROTEIN C IN A PLASMA SAMPLE | KABIVITRUM AB (SE) | 1991-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250002854-A1 | METHODS OF GENERATING POPULATIONS OF TUMOUR-INFILTRATING T CELLS | CD4, GZMB, PRF1 | NPC1 809/4885RAB9A 2037/4885MME 580/4885 |
| US-20190038670-A1 | METHODS OF GENERATING POPULATIONS OF TUMOUR-INFILTRATING T CELLS | CD4, GZMB, PRF1 | NPC1 718/4885RAB9A 2188/4885MME 682/4885 |
| US-20140037657-A1 | INHIBITION OF TUMOR GROWTH | STING1, VIP, MIF | NPC1 2139/4885RAB9A 4020/4885MME 92/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.